Irbesartan/Hydrochloorthiazide 1a Pharma

Irbesartan, the active ingredient in Irbesartan/Hydrochloorthiazide 1a Pharma, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in conjunction with a thiazide diuretic, and is prescribed for adults needing blood pressure control.

GNH USA supplies Irbesartan/Hydrochloorthiazide 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to lower blood pressure. - Essential hypertension: reduces systolic and diastolic pressure and lowers cardiovascular risk. - Hypertension requiring diuretic therapy: provides combined antihypertensive and diuretic effects for better control. - Resistant hypertension: adds an additional mechanism when monotherapy is insufficient.

Common Side Effects: - Dizziness: feeling light‑headed, especially after the first doses. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Increased urination: due to the diuretic component. - Electrolyte imbalance: low potassium or sodium levels. - Mild gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe dehydration: excessive fluid loss leading to low blood pressure. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty. - Blood disorders: such as agranulocytosis or leukopenia. - Liver injury: elevated liver enzymes or hepatitis.

Before initiating therapy, consider the following precautions: - Monitor blood pressure: check regularly to assess efficacy. - Assess renal function: evaluate serum creatinine and eGFR before and during treatment. - Check electrolytes: especially potassium and sodium levels. - Avoid in severe hepatic impairment: use with caution or consider alternatives. - Consider pregnancy status: category unknown; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original container.

Irbesartan/Hydrochlorothiazide may interact with several medicines. Review patient medication lists carefully. Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Lithium: increased lithium levels and toxicity. - NSAIDs: may reduce antihypertensive effect and impair renal function. - Cyclosporine: increased risk of renal dysfunction.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance antihypertensive effect. - Other diuretics: additive diuretic effect. - Antidiabetic agents: may increase hypoglycemic effect. - Antihistamines: may increase dizziness. - Alcohol: may potentiate hypotension.